DE9290035U1 - Pyridazinonessigsäuren - Google Patents

Pyridazinonessigsäuren

Info

Publication number
DE9290035U1
DE9290035U1 DE9290035U DE9290035U DE9290035U1 DE 9290035 U1 DE9290035 U1 DE 9290035U1 DE 9290035 U DE9290035 U DE 9290035U DE 9290035 U DE9290035 U DE 9290035U DE 9290035 U1 DE9290035 U1 DE 9290035U1
Authority
DE
Germany
Prior art keywords
methyl
oxo
dihydro
acid
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE9290035U
Other languages
German (de)
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Inc
Original Assignee
Pfizer Corp Belgium
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Inc filed Critical Pfizer Corp Belgium
Publication of DE9290035U1 publication Critical patent/DE9290035U1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30Phthalazines
    • C07D237/32Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE9290035U 1991-03-28 1992-03-09 Pyridazinonessigsäuren Expired - Lifetime DE9290035U1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67691991A 1991-03-28 1991-03-28

Publications (1)

Publication Number Publication Date
DE9290035U1 true DE9290035U1 (de) 1993-11-18

Family

ID=24716565

Family Applications (1)

Application Number Title Priority Date Filing Date
DE9290035U Expired - Lifetime DE9290035U1 (de) 1991-03-28 1992-03-09 Pyridazinonessigsäuren

Country Status (19)

Country Link
EP (1) EP0582643A1 (enExample)
JP (1) JPH06500793A (enExample)
CN (1) CN1065269A (enExample)
AU (1) AU658887B2 (enExample)
BR (1) BR9205810A (enExample)
CA (1) CA2107104A1 (enExample)
CZ (1) CZ387092A3 (enExample)
DE (1) DE9290035U1 (enExample)
FI (1) FI934222A7 (enExample)
HU (1) HUT67836A (enExample)
IE (1) IE920979A1 (enExample)
IL (1) IL101325A0 (enExample)
MX (1) MX9201414A (enExample)
NZ (1) NZ242152A (enExample)
PT (1) PT100301A (enExample)
TW (1) TW207998B (enExample)
WO (1) WO1992017446A2 (enExample)
YU (1) YU30392A (enExample)
ZA (1) ZA922238B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2240657T3 (es) 2001-02-28 2005-10-16 Pfizer Products Inc. Compuestos de sulfonilpiridazinona utiles como inhibidores de aldosa reductasa.
SE0100873D0 (sv) * 2001-03-13 2001-03-13 Astrazeneca Ab Method of treatment
YU71403A (sh) 2001-03-30 2006-05-25 Pfizer Products Inc. Piridazinoni kao inhibitori aldoza reduktaze
AU761191B2 (en) * 2001-05-24 2003-05-29 Pfizer Products Inc. Therapies for tissue damage resulting from ischemia
US7572910B2 (en) 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
CN111617072B (zh) * 2019-02-27 2023-06-20 苏州凯祥生物科技有限公司 一种高尿酸血症药物组合物及用于治疗高尿酸血症的药物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0676391B2 (ja) * 1987-06-09 1994-09-28 フアイザー・インコーポレイテツド ベンゾチアゾール等の複素環側鎖を有するオキソフタラジニル酢酸類の製造方法
FR2647676A1 (fr) * 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase

Also Published As

Publication number Publication date
AU1779692A (en) 1992-11-02
TW207998B (enExample) 1993-06-21
HUT67836A (en) 1995-05-29
BR9205810A (pt) 1994-06-28
YU30392A (sh) 1994-11-15
JPH06500793A (ja) 1994-01-27
EP0582643A1 (en) 1994-02-16
CZ387092A3 (en) 1994-02-16
HU9302728D0 (en) 1993-12-28
FI934222L (fi) 1993-09-27
PT100301A (pt) 1993-06-30
NZ242152A (en) 1994-07-26
MX9201414A (es) 1992-10-01
ZA922238B (en) 1993-09-27
CN1065269A (zh) 1992-10-14
AU658887B2 (en) 1995-05-04
FI934222A0 (fi) 1993-09-27
IL101325A0 (en) 1992-11-15
FI934222A7 (fi) 1993-09-27
WO1992017446A2 (en) 1992-10-15
WO1992017446A3 (en) 1992-11-26
IE920979A1 (en) 1992-10-07
CA2107104A1 (en) 1992-09-29

Similar Documents

Publication Publication Date Title
US4600724A (en) N-naphthoylglycine derivatives
DE69118565T2 (de) Thiazolidinderivate mit antidiabetischer Wirkung, ihre Herstellung und Anwendung
DE69018876T2 (de) Pyridazinon-Derivate.
DE69222096T2 (de) Tetrahydropyrrolo[1,2-a]Pyrazin-4-Spiro-3'-Pyrrolidin-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
DD146602A5 (de) Verfahren zur herstellung neuer spiro-oxazolidindione
DE69017174T2 (de) Substituierte Oxophtalazinyl-Essigsäuren und deren Analogen.
DE68906200T2 (de) Kondensierte pyrazol-3-oxo-propannitril-derivate und verfahren zu deren herstellung.
DE69128302T2 (de) Spiro-isochinolin-pyrrolidine und Analoge davon zur Verwendung als Aldose-Reduktase-Hemmer
CH678852A5 (enExample)
DE68915112T2 (de) Spiro-isochinolin-pyrrolidin-tetrone und Analoge davon, verwendbar als Aldosereduktase-Inhibitoren.
DD280320A5 (de) Herstellung von zwischenprodukten der oxophthalazinyl-essigsaeuren mit benzothiazol oder anderen heterocyclischen seitenketten
DE3784835T2 (de) Chinoxalinon-derivate.
DE9290035U1 (de) Pyridazinonessigsäuren
DE68910523T2 (de) Trizyklische 3-oxo-propannitril-derivate und verfahren zu deren herstellung.
DE3304019A1 (de) 3-acyloxy-1-phenyl-2-aminocarbonylindol-verbindungen sowie verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DD294257A5 (de) Verfahren zur herstellung von oxophthalazinyl-essigsaeuren, deren analogen und von zwischenprodukten
DE69625795T2 (de) Thiazolidinedionderivate mit antidiabetischen, hypolipidämischen und antihypertensiven Eigenschaften, Verfahren zu deren Herstellung und pharmazeutischen Zusammenstellungen, die sie enthalten
DE69131057T2 (de) 3-[1,Thiazolidinylbutyl-4-piperazinyl]-1H-Indazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente
DD254001A5 (de) Verfahren zur herstellung von heterocyclischen oxophtalazinylessigsaeuren
DE3135250A1 (de) Tricyclische thiazolyloxamate, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel
DE2427272C3 (de) 1-(2-(β-Naphthyloxy)-äthyl)-3-methyl -pyrazolon-(5), Verfahren sowie Verwendung als Antithrombotikum
DE3940074A1 (de) Kondensierte 3-oxo-propannitrilderivate und verfahren zu ihrer herstellung
DE69129941T2 (de) 1'-aminospiro-[isochinolin-4(1h),3'-pyrrolidin]- 1,2',3,5'-(2h)-tetrone und analoge verbindungen als inhibitoren der aldose reduktase in vivo
DE3642497A1 (de) Substituierte aminopropionsaeureamide, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung sowie die bei der herstellung anfallenden neuen zwischenprodukte
EP0213295B1 (de) Neue Thieno-1,2-thiazolderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate